Correlation Between Armata Pharmaceuticals and Cadrenal Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Armata Pharmaceuticals and Cadrenal Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Armata Pharmaceuticals and Cadrenal Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Armata Pharmaceuticals and Cadrenal Therapeutics, Common, you can compare the effects of market volatilities on Armata Pharmaceuticals and Cadrenal Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Armata Pharmaceuticals with a short position of Cadrenal Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Armata Pharmaceuticals and Cadrenal Therapeutics,.

Diversification Opportunities for Armata Pharmaceuticals and Cadrenal Therapeutics,

0.07

Correlation Coefficient

Armata Pharmaceuticals  Cadrenal Therapeutics,

Significant diversification

The 3 months correlation between Armata and Cadrenal is 0.07. Overlapping area represents the amount of risk that can be diversified away by holding Armata Pharmaceuticals and Cadrenal Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cadrenal Therapeutics, and Armata Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Armata Pharmaceuticals are associated (or correlated) with Cadrenal Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cadrenal Therapeutics, has no effect on the direction of Armata Pharmaceuticals i.e., Armata Pharmaceuticals and Cadrenal Therapeutics, go up and down completely randomly.

Pair Corralation between Armata Pharmaceuticals and Cadrenal Therapeutics,

Given the investment horizon of 90 days Armata Pharmaceuticals is expected to under-perform the Cadrenal Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Armata Pharmaceuticals is 1.3 times less risky than Cadrenal Therapeutics,. The stock trades about -0.07 of its potential returns per unit of risk. The Cadrenal Therapeutics, Common is currently generating about 0.12 of returns per unit of risk over similar time horizon. If you would invest  1,423  in Cadrenal Therapeutics, Common on December 29, 2024 and sell it today you would earn a total of  423.00  from holding Cadrenal Therapeutics, Common or generate 29.73% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Armata Pharmaceuticals  vs.  Cadrenal Therapeutics, Common

Armata Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Armata Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with abnormal performance in the last few months, the Stock's primary indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Cadrenal Therapeutics,

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Cadrenal Therapeutics, Common are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain forward-looking signals, Cadrenal Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Armata Pharmaceuticals and Cadrenal Therapeutics,

The main advantage of trading using opposite Armata Pharmaceuticals and Cadrenal Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Armata Pharmaceuticals position performs unexpectedly, Cadrenal Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cadrenal Therapeutics, will offset losses from the drop in Cadrenal Therapeutics,'s long position.

The idea behind Armata Pharmaceuticals and Cadrenal Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.